Cobitolimod
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.
Learn more